Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed some of the regulatory and legal hurdles that generic and biosimilar companies have to face on the road to market launch.
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed some of the regulatory and legal hurdles that generic and biosimilar companies have to face on the road to market launch.
Transcript
What regulatory and legal delays are expected to impact drug release dates?
Sure, so we're going to be speaking at AMCP [Academy of Managed Care Pharmacy Annual Meeting] in Chicago on both the traditional and specialty pipeline and what regulatory or legal or FDA issues impact drug launches. The first one that will hit is the drug patents and the drug patent thicket, there could be between 3 or 4 and 200 patents on a given molecule. And getting through all those patents inhibit multisource competition and at-risk launches. So, when generic or biosimilar companies are thinking about bringing these multisource products to market, there's sometimes unknown patent protection and if they launched during that unknown patent protection, it's an at-risk launch. So, we'll talk about that a little bit. Settlement agreements between brand companies and biosimilar and generic companies where they meet and decide, "OK, you guys can launch at this date." That avoids litigation and affects timing of launches. FDA advisory committee meetings, especially from a clinical perspective, impact approvals and launches; complete response letters, or CRLs, [there have been] a lot of those in the last few years. We'll mention that. And with the pandemic itself, inspection site delays have delayed launches of molecules over the last couple of years.
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More